Will Lupin turn healthy after a steep fall?

Shares of drug major Lupin have registered their 52-week lows on Tuesday at ₹1,280 on the NSE. The stock has been under severe pressure after Lupin received three observations relating to violation of production norms at Mandideep facility in Madhya Pradesh from the US Food and Drug Administration. Though the stock recovered to close at ₹1,404.95, traders are anxious whether Lupin shares will sustain the recovery from now.